# RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas

> **NCT07506668** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Affiliated Hospital of Nantong University** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** RN1701 injection

## Key facts

- **NCT ID:** NCT07506668
- **Lead sponsor:** Affiliated Hospital of Nantong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07506668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07506668, "RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07506668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*